EcoDrugPlus

Porcupine O-Acyltransferase

Ensembl ID : ENSMAMG00000024229
Gene Symbol: PORCN
2 Cross references
193 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSMAMG00000021248
Gene Symbol: KCNMA1
3 Cross references
235 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSMAMG00000017331
Gene Symbol: KCNMA1
3 Cross references
239 Possible Orthologues:

Potassium Channel Subfamily K Member 2-Like

Ensembl ID : ENSMAMG00000020407
Gene Symbol: LOC113122653
2 Cross references
209 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSMAMG00000027319
Gene Symbol: KCNK3A
3 Cross references
200 Possible Orthologues:

Potassium Intermediate/small Conductance Calcium-Activated Channel, Subfamily N, Member 4

Ensembl ID : ENSMAMG00000016296
Gene Symbol: KCNN4
2 Cross references
187 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSMAMG00000003175
Gene Symbol: KCNJ11
3 Cross references
188 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2a

Ensembl ID : ENSMAMG00000008518
Gene Symbol: KCNJ2A
3 Cross references
207 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSMAMG00000002093
Gene Symbol: KCNJ3
3 Cross references
224 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSMAMG00000000371
Gene Symbol: KCNJ5
1 Cross references
202 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSMAMG00000020549
Gene Symbol: KCNK2
2 Cross references
213 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSMAMG00000003531
Gene Symbol: KCNK9
3 Cross references
218 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).